25 June 2026
Advocate General Szpunar Makes Questionable Proposal to Relax Language Requirements for Labelling of Parallel-Traded Medicinal Products
10 min read
On 11 June 2026, Advocate General Szpunar delivered his non-binding Opinion concerning the application of labelling and national language requirements under Directive 2001/83/EC “on medicinal products for human use” to parallel-imported medicinal products.
The Opinion is highly questionable and, if followed by the Court of Justice of the European Union, would mark yet another step in the gradual erosion of public health protection in favour of the free movement of parallel-traded goods.
Attached is a note discussing the Opinion.
Attachments:
Key contacts
->
News & insights
1 min
read
read
News
Commission presents Action Plan on Cybersecurity and Artificial Intelligence
13 July 2026
6 min
read
read
News
Ongoing Disparagement Investigation – European Commission Discloses Additional Details of its Case and Sanofi Proposes Commitments
9 July 2026
1 min
read
read
News
Chambers Global Practice Guide: Merger Control 2026 now available
8 July 2026
1 min
read
read
Briefings
VBB secures lowest anti-dumping duty for Hankook in EU passenger car tyre investigation
7 July 2026
1 min
read
read
News
Belgian Competition Authority Conditionally Approves Acquisition of Press Activities IPM Presse by Rossel
6 July 2026
2 min
read
read
News
European Commission Opens First Formal Abuse of Dominance Investigation in Medical Devices Sector
2 July 2026
5 min
read
read
News
Court of Justice of European Union Rules that Pay-for-Delay Patent Settlements May Restrict Competition ‘by Object’
3 February 2020
5 min
read
read
News
Complaint by Greek Medicine Wholesaler Against Switch to Direct Distribution Dismissed by European Commission
30 June 2026
